We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

253 hedge funds and large institutions have $462M invested in Iovance Biotherapeutics in 2025 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 81 increasing their positions, 79 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

67% more call options, than puts

Call options by funds: $7.47M | Put options by funds: $4.47M

22% more capital invested

Capital invested by funds: $379M → $462M (+$83M)

3% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 79

3% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 40

1% less funds holding

Funds holding: 255 → 253 (-2)

7.1% less ownership

Funds ownership: 65.97% → 58.87% (-7.1%)

Holders
253
Holders Change
-2
Holders Change %
-0.78%
% of All Funds
3.32%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
41
Increased
81
Reduced
79
Closed
40
Calls
$7.47M
Puts
$4.47M
Net Calls
+$3M
Net Calls Change
+$1.97M

Top Buyers

Rank Fund Capital Flow
1
PAI
Palo Alto Investors
California
+$9.89M
2
State Street
State Street
Massachusetts
+$8.07M
3
BlackRock
BlackRock
New York
+$6.42M
4
Bank of America
Bank of America
North Carolina
+$5.31M
5
ICM
Invenomic Capital Management
Massachusetts
+$5.31M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$11.6M
2
Renaissance Technologies
Renaissance Technologies
New York
-$8.41M
3
LFCM
Long Focus Capital Management
Puerto Rico
-$6.38M
4
SCM
Soleus Capital Management
Connecticut
-$5.4M
5
Two Sigma Investments
Two Sigma Investments
New York
-$4.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
26
Jane Street
New York
$3.07M -$1.4M -593,909 -30%
CWG
27
C WorldWide Group
Denmark
$2.73M – – –
N
28
Nuveen
North Carolina
$2.72M +$1.12M +472,731 +61%
JP Morgan Chase
29
JP Morgan Chase
New York
$2.66M -$45K -19,040 -2%
RPAM
30
Rhenman & Partners Asset Management
Sweden
$2.38M +$1.06M +450,000 +69%
Two Sigma Advisers
31
Two Sigma Advisers
New York
$2.3M -$3.01M -1,275,900 -55%
SCM
32
Soleus Capital Management
Connecticut
$2.12M -$5.4M -2,285,000 -70%
Invesco
33
Invesco
Georgia
$2.05M +$688K +291,521 +45%
Barclays
34
Barclays
United Kingdom
$2.03M +$124K +52,347 +6%
UBS Group
35
UBS Group
Switzerland
$2.03M -$1.99M -842,908 -47%
SPS
36
Susquehanna Portfolio Strategies
Pennsylvania
$1.98M +$2.15M +912,099 New
Bank of New York Mellon
37
Bank of New York Mellon
New York
$1.75M +$62.7K +26,557 +3%
CM
38
CM Management
Florida
$1.52M – – –
QF
39
QVT Financial
New York
$1.47M – – –
VC
40
Voss Capital
Texas
$1.41M -$53.3K -22,570 -3%
Deutsche Bank
41
Deutsche Bank
Germany
$1.4M +$59.1K +25,010 +4%
LPL Financial
42
LPL Financial
California
$1.33M +$300K +127,070 +26%
Aberdeen Group
43
Aberdeen Group
United Kingdom
$1.32M +$215K +90,921 +18%
WP
44
Woodline Partners
California
$1.23M – – –
HWAM
45
Hennion & Walsh Asset Management
New Jersey
$1.18M +$106K +45,101 +9%
TCM
46
Tang Capital Management
California
$1.18M -$2.97M -1,256,240 -70%
Swiss National Bank
47
Swiss National Bank
Switzerland
$1.12M +$39.9K +16,900 +3%
MCP
48
Mirador Capital Partners
California
$1.12M +$1.22M +515,025 New
Rafferty Asset Management
49
Rafferty Asset Management
New York
$1.05M +$450K +190,522 +65%
UBS AM
50
UBS AM
Illinois
$1.05M -$414K -175,428 -27%
1
2
3 4 5

IOVA Hedge Fund Activity: Q3 2025 in Review

253 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q3 2025, worth a combined $462M — up 22% from $379M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new IOVA positions and 40 closed out — a net gain of 1 holder — while 81 added to existing stakes and 79 trimmed.

The largest buyer was Palo Alto Investors, adding an estimated $9.89M. The largest seller was Millennium Management, cutting an estimated $11.6M.

  • 253 institutional investors held Iovance Biotherapeutics (IOVA) as of Q3 2025, down from 255 in Q2 2025.
  • Funds reported $462M of Iovance Biotherapeutics stock for Q3 2025, up 22% quarter-over-quarter.
  • 41 funds opened new Iovance Biotherapeutics positions in Q3 2025 and 40 closed out, a net change of +1 holder.
  • The largest Iovance Biotherapeutics buyer in Q3 2025 was Palo Alto Investors, an estimated $9.89M added.
  • The largest Iovance Biotherapeutics seller in Q3 2025 was Millennium Management, an estimated $11.6M sold.

Based on aggregated 13F filings for Q3 2025.